BME100 s2014:T Group14 L2
|BME 100 Fall 2013|| Home |
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
LAB 2 WRITE-UP
The two clinical trials between rats and elderly both yielded increased levels of inflammotin in the blood, however, there is a significant statistical difference between them. Examining the p-value, the human trial resulted in much more reliable statistics (p-value= 1.4 * 10^-16) than the rat study (p-value=0.590027). Therefore if a second clinical trial were to be constructed from the basis of these two trials, it should follow a model of the human clinical trials and not one of the rat trial. Concerning the variation in dosage of the LPS, scalar similarities exist between the two studies. In humans, when the dosage increased to 10mg the inflammotin levels greatly increased from their values at a 5mg dosage. In the rat study, the levels increased at a 10mg dosage comparative to the placebo (0mg dose), although not to the degree found in the human study. This indicates that, if a second trial were to be constructed, the rat study should have more dosage increments between 0mg and 10mg with additional increments greater than 10mg. This will allow more data points to analyze the levels of inflammotin in the rats blood. In conclusion, LPS showed increased levels of inflammotin in the blood in both trials, therefore it would be constructive to conclude that LPS could be clinically applied to raise levels of inflammation in the blood of the elderly.